CNS Pharmaceuticals, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

CNSP$3.85-2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2024 and 2023

Balance Sheets

	December 31, 2024	December 31, 2023
Assets
Current Assets:
Cash and cash equivalents	$6,461,378	$548,721
Deferred offering costs	20,637	202,859
Subscription receivable	882,539	–
Prepaid expenses and other current assets	1,293,954	839,590
Total current assets	8,658,508	1,591,170
Noncurrent Assets:
Prepaid expenses, net of current portion	36,430	104,750
Property and equipment, net	6,005	4,933
Total noncurrent assets	42,435	109,683
Total Assets	$8,700,943	$1,700,853
Liabilities and Stockholders' Equity (Deficit)
Current Liabilities:
Accounts payable and accrued expenses	$2,198,260	$5,832,162
Notes payable	326,072	300,806
Total current liabilities	2,524,332	6,132,968
Total Liabilities	2,524,332	6,132,968
Commitments and contingencies	–	–
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding	–	–
Common stock, $0.001 par value, 300,000,000 shares authorized and 1,413,556 and 2,486 shares issued and outstanding, respectively	1,414	2
Additional paid-in capital	90,599,901	65,134,786
Accumulated deficit	(84,424,704)	(69,566,903)
Total Stockholders' Equity (Deficit)	6,176,611	(4,432,115)
Total Liabilities and Stockholders' Equity (Deficit)	$8,700,943	$1,700,853

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.